期刊文献+

175例淀粉样变性患者临床特点及预后分析 被引量:5

Clinical characteristics and prognosis analysis of 175 patients with amyloidosis
原文传递
导出
摘要 淀粉样变性是一类系统性疾病,由"罕见"变"常见"需引起重视。本研究回顾分析本中心近20年来175例淀粉样变性患者的临床资料,总体评估患者资料,探讨相关影响因素,以期提高早期确诊率,改善患者预后。研究结果显示,该病好发年龄为50~59岁(占34.85%),且年龄越大治疗效果越差(OR=1.064,95%CI 1.030~1.099,P<0.001);最易累及肾脏(42.86%)和心脏(21.71%);主要表现为蛋白尿、水肿、胸闷气喘、皮肤瘙痒及色素沉着、腹部胀痛、腹水、肝大、低血压等。早期选择有效治疗方案如接受激素+免疫抑制剂/血液透析/化疗/自体干细胞移植/手术等治疗,则治疗效果更佳(OR=3.706,95%CI 1.866~7.352,P<0.001),且是否接受有效治疗方案是预后的独立影响因素(HR=2.567,95%CI 1.291~5.103,P=0.007)。年龄增大(HR=1.049,95%CI 1.020~1.078,P=0.001)、低血压(HR=2.431,95%CI 1.149~5.141,P=0.020)、心脏受累(HR=6.556,95%CI 3.401~12.640,P<0.001)、多器官受累(HR=2.315,95%CI 1.107~4.840,P=0.026)、血清白蛋白降低(HR=2.477,95%CI 1.219~5.034,P=0.012)、估计肾小球滤过率(eGFR)降低(HR=2.215,95%CI 1.205~4.070,P=0.010)、B型钠尿肽(BNP)升高(HR=3.962,95%CI 1.357~11.574,P=0.012)、肌钙蛋白T(TnT)升高(HR=2.872,95%CI 1.042~7.915,P=0.041)亦是预后的独立影响因素,可增加死亡风险。因此,在诊疗过程中,临床医师需密切监测这些指标变化,早期诊断及采取有效治疗措施,以改善淀粉样变性患者的治疗效果及预后。
作者 于澈 赵雪 王荣 Yu Che;Zhao Xue;Wang Rong(Department of Nephrology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Cheeloo College of Medicine of Shandong University,Jinan 250012,China)
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2021年第3期224-228,共5页 Chinese Journal of Nephrology
基金 国家自然科学基金 (81770723)。
  • 相关文献

参考文献1

二级参考文献19

  • 1曾彩虹,刘志红,李世军,刘莉莉,黎磊石.遗传性纤维蛋白原A-α链淀粉样变性[J].肾脏病与透析肾移植杂志,2007,16(1):37-42. 被引量:7
  • 2Merlini G,Bellotti V. Molecular mechanisms of amyloidosis[J].New England Journal of Medicine,2003.583-596.
  • 3Picken MM. New insights into systemic amyloidosis:the importance of diagnosis of specific type[J].Current Opinion in Nephrology and Hypertension,2007,(3):196-203.doi:10.1097/MNH.0b013e3280bdc0db.
  • 4Qu Z,Zheng X,Wang SX. Clinical and pathological features of renal amyloidosis:an analysis of 32 patients in a single Chinese centre[J].Nephrology,2010.102-107.
  • 5Lachmann HJ,Booth DR,Booth SE. Misdiagnosis of hereditary amyloidosis as AL(primary)amyloidosis[J].New England Journal of Medicine,2002.1786-1791.
  • 6yon Hutten H,Mihatsch M,Lobeck H. Prevalence and origin of amyloid in kidney biopsies[J].American Journal of Surgical Pathology,2009.1198-1205.
  • 7Comenzo RL,Zhou P,Fleisher M. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis:patients can have both monoclonal gammopathies and hereditary amyloid proteins[J].Blood,2006.3489-3491.
  • 8Bergesio F,Ciciani AM,Santostefano M. Renal involvement in systemic amyloidosis-an Italian retrospective study on epidemiological and clinical data at diagnosis[J].Nephrology Dialysis Transplantation,2007.1608-1618.
  • 9Larsen CP,Walker PD,Weiss DT. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies[J].Kidney International,2010.816-819.
  • 10Sen S,Sarsik B. A proposed histopathologic classification,scoring,and grading system for renal amyloidosis:standardization of renal amyloid biopsy report[J].Archives of Pathology and Laboratory Medicine,2010.532-544.

共引文献10

同被引文献29

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部